Development of cardiovascular and all-cause mortality risk prediction models for maintenance hemodialysis patients based on metabolomics
Abstract Introduction The outcome of maintenance hemodialysis (MHD) remains poor, with cardiovascular death accounting for more than half of all-cause death cases. In this study, cardiovascular mortality and all-cause mortality prediction models were developed to investigate the predictive role of m...
Saved in:
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2025-07-01
|
| Series: | BMC Nephrology |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s12882-025-04291-0 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Summary: | Abstract Introduction The outcome of maintenance hemodialysis (MHD) remains poor, with cardiovascular death accounting for more than half of all-cause death cases. In this study, cardiovascular mortality and all-cause mortality prediction models were developed to investigate the predictive role of metabolites in MHD patients. Methods Clinical and metabolomics data of 135 hemodialysis patients from a single center were collected with a 6-year follow-up. Univariate Cox regression and random forest were respectively applied to preliminarily screen clinical and metabolomics characteristics, followed by multivariate Cox regression for identifying features predicting cardiovascular or all-cause mortality. Multivariate Cox proportional regression risk models were constructed using clinical, metabolomics, and combined features. Subgroup survival differences were compared via risk score stratification. Results The combined model showed significant superiority in predicting cardiovascular mortality (3-year AUC = 0.901, 5-year AUC = 0.876), surpassing the clinical-only model (0.868/0.826) and metabolomics-only model (0.659/0.641). For all-cause mortality, the combined model demonstrated modest improvement (0.859/0.834) but still outperformed the metabolomics model (0.534/0.653). Thirty 5-fold cross-validations confirmed stable performance. High-risk groups had significantly higher cumulative mortality than low-risk groups (p < 0.0001). Conclusion The metabolomics-alone model showed limited predictive performance, but its synergistic integration with clinical indicators further improved the predictive performance of mortality risk models, particularly for cardiovascular mortality. |
|---|---|
| ISSN: | 1471-2369 |